Douglas Williams, Ph.D., will leave Biogen at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Dr. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy.
Responsibility for Biogen Research and Development will be assumed by Alfred Sandrock, M.D., Ph.D., senior vice president and Chief Medical Officer, and Spyros Artavanis-Tsakonas, Ph.D., senior vice president and Chief Scientific Officer. Both Dr. Sandrock and Dr. Artavanis-Tsakonas currently serve on the executive management team.
View the full release here.